+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Pipeline Review, H2 2018

  • ID: 4667890
  • Drug Pipelines
  • November 2018
  • Region: Global
  • 106 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AB Science SA
  • Asana BioSciences LLC
  • Clevexel Pharma SAS
  • Gilead Sciences Inc
  • Hutchison MediPharma Ltd
  • Rigel Pharmaceuticals Inc
  • MORE
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Pipeline Review, H2 2018

Summary

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) pipeline Target constitutes close to 26 molecules. The latest report Tyrosine Protein Kinase SYK - Pipeline Review, H2 2018, outlays comprehensive information on the Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Spleen tyrosine kinase, also known as Syk, is an enzyme encoded by the SYK gene. It regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. It assembles into signaling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosine-phosphorylated ITAM domains. The association with the receptor can also be indirect and mediated by adapter proteins containing ITAM or partial hemITAM domains. The phosphorylation of the ITAM domains is generally mediated by SRC subfamily kinases upon engagement of the receptor. More rarely signal transduction via SYK could be ITAM-independent.

The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 8, 3, 11 and 2 respectively. Report covers products from therapy areas Immunology, Oncology, Hematological Disorders, Dermatology, Gastrointestinal, Ophthalmology, Central Nervous System, Respiratory, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders which include indications Rheumatoid Arthritis, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Ulcerative Colitis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Allergic Conjunctivitis, Asthma, B-Cell Chronic Lymphocytic Leukemia, Blood Cancer, Marginal Zone B-cell Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Acquired (Autoimmune) Hemolytic Anemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Allergies, Alopecia, Alzheimer's Disease, Arthritis, B-Cell Non-Hodgkin Lymphoma, Bladder Cancer, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Cutaneous Lupus Erythematosus, Cutaneous T-Cell Lymphoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gastric Cancer, Glomerulonephritis, Hand Dermatitis, Keratoconjunctivitis Sicca (Dry Eye), Kidney Transplant Rejection, Lupus Erythematosus, Lupus Nephritis, Metastatic Breast Cancer, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Post-Transplant Lymphoproliferative Disorder, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Sicca Syndrome (Sjogren), Subacute Cutaneous Lupus Erythematosus (SCLE), Systemic Lupus Erythematosus and Vitiligo.

Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AB Science SA
  • Asana BioSciences LLC
  • Clevexel Pharma SAS
  • Gilead Sciences Inc
  • Hutchison MediPharma Ltd
  • Rigel Pharmaceuticals Inc
  • MORE
Introduction

Report Coverage

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Overview

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Companies Involved in Therapeutics Development

AB Science SA

Almirall SA

Archer Pharmaceuticals Inc

Asana BioSciences LLC

Beijing Hanmi Pharmaceutical Co Ltd

Celgene Corp

Clevexel Pharma SAS

Fujifilm Holdings Corporation

Genosco Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Hutchison MediPharma Ltd

Japan Tobacco Inc

Levolta Pharmaceuticals Inc

Millennium Pharmaceuticals Inc

Portola Pharmaceuticals Inc

Rigel Pharmaceuticals Inc

Taiho Pharmaceutical Co Ltd

TopiVert Ltd

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Drug Profiles

AB-8779 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASN-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-509 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cerdulatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CVXL-0074 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

entospletinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FF-10102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fostamatinib disodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-492429 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-9876 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2646264 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HMPL-523 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JTE-852 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LAS-189386 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nilvadipine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRT-2761 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SKIO-703 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit SYK and JAK for Autoimmune Disorders and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit SYK for Diffuse Large B-Cell Lymphoma and Peripheral T-Cell Lymphoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Spleen Tyrosine Kinase for Immunology and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-659 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAS-05567 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOP-1210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOP-1288 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOP-1630 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOP-1890 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Dormant Products

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Discontinued Products

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Product Development Milestones

Featured News & Press Releases

Nov 01, 2018: Portola Pharmaceuticals to present new interim phase 2 results for Cerdulatinib during an oral session at the 60th American Society of Hematology (ASH) Annual Meeting

Oct 18, 2018: Chi-Med Initiates a Phase I Trial of HMPL-523 in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia in China

Oct 11, 2018: Rigel receives EMA validation of the marketing authorization application for Fostamatinib Disodium Hexahydrate in chronic immune thrombocytopenia (ITP) in adult patients

Sep 25, 2018: Portola Pharmaceuticals receives FDA Orphan Drug Designation for Cerdulatinib, an oral Syk/JAK inhibitor for the treatment of Peripheral T-Cell Lymphoma

Sep 10, 2018: Asana BioSciences to present late-breaking clinical and biomarker data for its JAK/SYK inhibitor ASN002 at the European Academy of Dermatology and Venereology Annual Congress

Jul 20, 2018: Asana starts Phase llb trial of ASN002 for atopic dermatitis

Jun 20, 2018: Rigel Announces Poster Presentations at FOCIS Annual Meeting

Jun 18, 2018: US Bioservices selected by Rigel Pharmaceuticals to dispense TAVALISSE (fostamatinib disodium hexahydrate) Tablets

Jun 12, 2018: Rigel to present phase 2 results for Fostamatinib in Autoimmune Hemolytic Anemia at EHA

Jun 04, 2018: New Interim Phase 2a Study Results Demonstrate Broad Clinical Activity of Portola Pharmaceuticals’ Oral SYK/JAK Inhibitor Cerdulatinib

May 30, 2018: Rigel Appoints Dean Schorno as Chief Financial Officer

May 29, 2018: Rigel Announces Availability of TAVALISSE (fostamatinib disodium hexahydrate) in the U.S.

May 29, 2018: TAVALISSE (fostamatinib disodium hexahydrate) Approved by FDA, Available for Order at Biologics

Apr 30, 2018: TAVALISSE (fostamatinib disodium hexahydrate) Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus Placebo

Apr 25, 2018: Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Products under Development by Companies, H2 2018 (Contd..5), H2 2018

Products under Development by Companies, H2 2018 (Contd..6), H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by AB Science SA, H2 2018

Pipeline by Almirall SA, H2 2018

Pipeline by Archer Pharmaceuticals Inc, H2 2018

Pipeline by Asana BioSciences LLC, H2 2018

Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2018

Pipeline by Celgene Corp, H2 2018

Pipeline by Clevexel Pharma SAS, H2 2018

Pipeline by Fujifilm Holdings Corporation, H2 2018

Pipeline by Genosco Inc, H2 2018

Pipeline by Gilead Sciences Inc, H2 2018

Pipeline by GlaxoSmithKline Plc, H2 2018

Pipeline by Hutchison MediPharma Ltd, H2 2018

Pipeline by Japan Tobacco Inc, H2 2018

Pipeline by Levolta Pharmaceuticals Inc, H2 2018

Pipeline by Millennium Pharmaceuticals Inc, H2 2018

Pipeline by Portola Pharmaceuticals Inc, H2 2018

Pipeline by Rigel Pharmaceuticals Inc, H2 2018

Pipeline by Taiho Pharmaceutical Co Ltd, H2 2018

Pipeline by TopiVert Ltd, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Dormant Products, H2 2018 (Contd..2), H2 2018

Dormant Products, H2 2018 (Contd..3), H2 2018

Discontinued Products, H2 2018

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AB Science SA
  • Almirall SA
  • Archer Pharmaceuticals Inc
  • Asana BioSciences LLC
  • Beijing Hanmi Pharmaceutical Co Ltd
  • Celgene Corp
  • Clevexel Pharma SAS
  • Fujifilm Holdings Corporation
  • Genosco Inc
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Hutchison MediPharma Ltd
  • Japan Tobacco Inc
  • Levolta Pharmaceuticals Inc
  • Millennium Pharmaceuticals Inc
  • Portola Pharmaceuticals Inc
  • Rigel Pharmaceuticals Inc
  • Taiho Pharmaceutical Co Ltd
  • TopiVert Ltd
Note: Product cover images may vary from those shown
Adroll
adroll